HARMONI-GI1 at the @myESMO #ESMO26 #Presidential of CisGem + #ivonescimab vs durvalumab in #firstline #BiliaryMalignancies

✅OS HR 0.75, mOS 12.1vs14.9
✅PFS HR 0.61, mPFS 6.8vs8.4
✅ORR 53.8vs32.5

🌐China only
BUT
😊This is a positive trial

🥳VEGF is back

#ESMOAmbassadors